Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 24, 2007, Pages 6691-6696

  Blagg, Julian ^a   Allerton, Charlotte M N ^a   Batchelor, David V J ^a   Baxter, Andrew D ^a   Burring, Denise J ^a   Carr, Christopher L ^a   Cook, Andrew S ^a   Nichols, Carly L ^a   Phipps, Joanne ^a   Sanderson, Vivienne G ^a   Verrier, Hugh ^a   Wong, Stephen ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

Arylmorpholine; Dopamine D3 receptor agonist; Intranasal delivery; Synthesis

Indexed keywords

APOMORPHINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR STIMULATING AGENT; MORPHOLINE DERIVATIVE; PHENYLEPHRINE; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; PRAMIPEXOLE; QUINELORANE; ROPINIROLE; TERBUTALINE;

ANIMAL CELL; ARTICLE; DISTRIBUTION VOLUME; DOG; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; NONHUMAN; RAT; STEREOSPECIFICITY;

ADMINISTRATION, INTRANASAL; ANIMALS; CRYSTALLOGRAPHY, X-RAY; DOGS; DOPAMINE AGONISTS; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; RATS; RECEPTORS, DOPAMINE D3; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 35848957888     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.10.059     Document Type: Article

References (23)

1. Giuliano F., Allard J., Rampin O., Droupy S., Benoit G., Alexandre L., and Bernabe J. Int. J. Impot. Res. 13 (2001) 110
2. Melis M.A., and Argiolas A. Neurosci. Biobehav. Rev. 19 (1995) 19
3. Rosen R.C., and Ashton A.K. Arch. Sex. Behav. 22 (1993) 521
4. Dula E., Bukofzer S., Perdok R., and George M. Eur. Urol. 39 (2001) 558
5. MacLennan K.M., Boshier A., Wilton L.V., and Shakir S.A.W. Brit. J. Urol. Int. 98 (2006) 125
6. Montorsi F. Int. J. Impot. Res. 15 (2003) S7
7. Van der Graaf P.H., Wayman C.P., Baxter A.D., Cook A.S., and Wong S.K. Chem. Abstr. 139 (2003) 63348 WO 03/051370, 2003
8. Boeckler F., and Gmeiner P. Pharmacol. Therapeut. 112 (2006) 281
9. Cannon J.G. Progress in Drug Research. In: Jucker E. (Ed). Chapter 9: Dopamine Agonists: Structure-activity Relationships vol. 29 (1985), Birkhauser Verlag, Basel 381
10. Van Vliet L.A., Rodenhuis N., Dijkstra D., Wikstrom H., Pugsley T.A., Serpa K.A., Meltzer L.T., Heffner T.G., Wise L.D., Lijiness M.E., Huff R.M., and Svensson K. J. Med. Chem. 43 (2000) 2871
11. Allerton C.M.N., Baxter A.D., Cook A.S., Hepworth D., and Wong S.K. Chem. Abstr. 141 (2004) 71567 WO 04/052372, 2004
12. The enantiomers were separated by chiral column chromatography at room temperature (Chiralpak AD250, 20 mm column) eluting with hexane: isopropyl alcohol: diethylamine (70:30:0.05) to give R(-)-3-(4-propylmorpholin-2-yl)phenol (26) (e.e. >99.5%) followed by S(+)- 3-(4-propylmorpholin-2-yl)phenol (27) (e.e. >99%).
13. Crystallographic data (excluding structure factors) for the structures in this paper have been deposited at the Cambridge Crystallographic Data Centre for small molecules and allocated the deposition number CCDC 661368. Copies of data can be obtained free of charge on application to CCDC, 12 Union Road, Cambridge, CB2 1EZ, UK.
14. Yin H., Bennet G., and Jones J.P. Chem-Biol. Interact. 90 (1994) 47
15. Soffers A.E.M.F., Veeger C., and Rietjens I.M.C.M. Xenobiotica 24 (1994) 759
16. The enantiomers were separated by chiral column chromatography at room temperature (Chiralpak AD250, 20 mm column) eluting with hexane: isopropyl alcohol (90:10) to give R-(+)-2-Fluoro-5-(4-propylmorpholin-2-yl)phenol (44) (e.e. >99.5%) followed by S-(-)-2-Fluoro- 5-(4-propylmorpholin-2-yl)phenol (45) (e.e. >99%).
17. The Pharmacological Basis of Therapeutics (IX edition), Gilman, A. Ed.; McGraw-Hill, 1996, 1785.
18. The Pharmacological Basis of Therapeutics, (X edition), Gilman, A. Ed.; McGraw-Hill, 2001, 1994.
19. The enantiomers were separated by chiral column chromatography at room temperature (Chiralpak AD250, 20 mm column) eluting with hexane: isopropyl alcohol (80:20) to give R-5-(4-propylmorpholin-2-yl)benzene-1,3-diol (46) (e.e. = 99%) followed by S-5-(4-propylmorpholin-2-yl)benzene-1,3-diol (47) (e.e. = 96%).
20. Sam E., Jeanjean A.P., Maloteaux J.M., and Verbeke N. Eur. J. Drug Metab. Ph. 20 (1995) 27
21. Arora P., Garg S., and Sharma S. Drug Discov. Today 7 (2002) 967
22. Behl C.R., Pimplaskar H.J., Sileno A.P., DeMeireles J., and Romeo V.D. Adv. Drug Delivery Rev. 29 (1998) 89
23. The pharmacokinetics of compound 26 were determined following single intravenous and intranasal doses to male rats and to male (n = 2) and female (n = 2) dogs. Compound 26 was freshly prepared in saline solution. In rat, the intravenous dose was administered as a bolus dose of 1 mg/kg. The intranasal dose was administered via a Gilson pipette (20 μl) into one nostril to give a final dose of 0.5 and 2 mg/kg. In dog, the intravenous dose was administered as an intravenous infusion over a 10-min period at a rate of 3 ml/kg/h of a 0.2 mg/ml solution, to give a final dose of 0.1 mg/kg. The intranasal dose was administered via a Pfeiffer device (100 μl) into one nostril to give a final dose of 0.1 and 0.3 mg/kg.